BioCentury | Feb 8, 2020
Finance

Forbion leads Azafaros’ €25M series A, with rare disease vet as chair

...Non-lysosomal glucosylceramidase GCS - Glucosylceramide synthase Paul Bonanos, Associate Editor Forbion Capital Partners Glucosidase beta bile acid (GBA2)Glucosylceramide...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

...allow it to be best in class for this target in MS. Targets GCS - Glucosylceramide...
BioCentury | Dec 6, 2019
Targets & Mechanisms

A view of immune reprogramming from ASH

...team shows macrophages from patients with Gaucher's disease, which accumulate high levels of the sphingolipid glucosylceramide...
BioCentury | Sep 11, 2019
Product Development

Pharmas’ challenge: learning from rare disease units while leaving them alone

...kidney disease and in Phase II for Gaucher and Fabry diseases. But the small molecule glucosylceramide...
...NYSE:TAK), Tokyo, Japan Yumanity Therapeutics LLC, Cambridge, Mass. Targets DHODH -- dihydroorotate dehydrogenase GCS -- Glucosylceramide...
BioCentury | Mar 9, 2018
Emerging Company Profile

Reviving lixivaptan

...five companies have compounds in the clinic for ADPKD. The most advanced is venglustat, a glucosylceramide...
...Md. Mark Zipkin, Staff Writer Chiesi Farmaceutici S.p.A. Otsuka Pharmaceutical Co. Ltd. Palladio Biosciences Inc. Sanofi U.S. Food and Drug Administration (FDA) Glucosylceramide...
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

...DNA ligase 4 (LIG4) 4 0 Fatty acid binding protein 4 adipocyte (FABP4) 5 0 Glucosylceramide (GlcCer)...
BioCentury | Jul 28, 2017
Regulation

Ganging up in rare disease

...has started a required pediatric trial of Cerdelga eliglustat tartrate, a ceramide analog that inhibits glucosylceramide...
...an oral encapsulated plant cell-expressed recombinant form of human glucocerebrosidase (GBA; GCase); GS/SAR402671 is a glucosylceramide...
BioCentury | Jul 21, 2017
Company News

NICE final guidance recommends Sanofi's Cerdelga for Type I Gaucher's

...in cost savings compared with ERT. In 2014, FDA approved the ceramide analog that inhibits glucosylceramide...
...Sept. 1, 2014 ). Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Alex Himes Cerdelga eliglustat tartrate Sanofi Cytochrome P450 2D6 (CYP2D6) Glucosylceramide...
BioCentury | Feb 16, 2017
Clinical News

GZ/SAR402671: Ph II MOVES-PD started

...with PD. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: GZ/SAR402671 , GZ402671 Business: Neurology Molecular target: Glucosylceramide...
...III and Hoehn and Yahr scores at 52 weeks Status: Phase II started Milestone: NA Julian Zhu GZ/SAR402671 GZ402671 Sanofi Glucosylceramide...
BioCentury | Jan 20, 2017
Emerging Company Profile

Aiming for durability

...BioCentury’s BCIQ database, the Fabry’s clinical pipeline consists of enzyme replacement therapies, along with two glucosylceramide...
Items per page:
1 - 10 of 65